Kenvue Inc. (NYSE:KVUE) Shares Sold by Northeast Investment Management

Northeast Investment Management cut its position in shares of Kenvue Inc. (NYSE:KVUE) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,163 shares of the company’s stock after selling 11,291 shares during the quarter. Northeast Investment Management’s holdings in Kenvue were worth $1,840,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Grove Bank & Trust boosted its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter worth approximately $29,000. Riverview Trust Co purchased a new stake in Kenvue in the third quarter valued at approximately $30,000. Fortitude Family Office LLC increased its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Kenvue during the third quarter worth approximately $35,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $20.23 on Friday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $38.79 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The firm’s fifty day moving average price is $21.54 and its 200 day moving average price is $21.95.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts forecast that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Bank of America boosted their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.